Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.6534
-0.0182 (-2.71%)
At close: Jul 31, 2026, 4:00 PM EDT
0.6451
-0.0083 (-1.27%)
After-hours: Jul 31, 2026, 7:39 PM EDT
Humacyte Employees
Humacyte had 184 employees as of December 31, 2025. The number of employees decreased by 36 or -16.36% compared to the previous year.
Employees
184
Change (1Y)
-36
Growth (1Y)
-16.36%
Revenue / Employee
$10,957
Profits / Employee
-$517,484
Market Cap
176.18M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 184 | -36 | -16.36% | 184 | 0 |
| Dec 31, 2024 | 220 | 35 | 18.92% | 218 | 2 |
| Dec 31, 2023 | 185 | 21 | 12.80% | 183 | 2 |
| Dec 31, 2022 | 164 | 18 | 12.33% | 164 | 0 |
| Dec 31, 2021 | 146 | - | - | 145 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Voyager Therapeutics | 141 |
| MediWound | 121 |
| Alector | 103 |
| Precision BioSciences | 66 |
| Armata Pharmaceuticals | 61 |
| Camp4 Therapeutics | 48 |
| NovaBridge Biosciences | 30 |
HUMA News
- 4 days ago - Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting - GlobeNewsWire
- 17 days ago - Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access - GlobeNewsWire
- 6 weeks ago - Humacyte Slides: Corporate presentation - Filings
- 6 weeks ago - Humacyte Transcript: Study result - Transcripts
- 6 weeks ago - Humacyte Press release: Study result - Filings
- 6 weeks ago - Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting - GlobeNewsWire
- 7 weeks ago - Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Humacyte, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewsWire